Multiple sclerosis (MS) is an autoimmune life-threatening disease, afflicting millions of people worldwide. Although the disease is non-curable, considerable therapeutic advances have been achieved through molecular immunotherapeutic approaches, such as peptides vaccination, administration of monoclonal antibodies, and immunogenic copolymers. The main aims of these therapeutic strategies are to shift the MS-related autoimmune response towards a non-inflammatory T helper 2 (Th2) cells response, inactivate or ameliorate cytotoxic autoreactive T cells, induce secretion of anti-inflammatory cytokines, and inhibit recruitment of autoreactive lymphocytes to the central nervous system (CNS). These approaches can efficiently treat autoimmune encephalomyelitis (EAE), an essential system to study MS in animals, but they can only partially inhibit disease progress in humans. Nevertheless, modern immunotherapeutic techniques remain the most promising tools for the development of safe MS treatments, specifically targeting the cellular factors that trigger the initiation of the disease.

中文翻译：

---

对多发性硬化症治疗的分子干预。

多发性硬化症（MS）是一种威胁生命的自身免疫性疾病，困扰着全球数百万人。尽管该疾病是无法治愈的，但是通过分子免疫治疗方法已经取得了可观的治疗进展，例如肽疫苗接种，单克隆抗体的给药和免疫原性共聚物。这些治疗策略的主要目的是将与MS相关的自身免疫反应转变为非炎性T辅助2（Th2）细胞反应，灭活或改善细胞毒性自身反应性T细胞，诱导抗炎细胞因子的分泌，并抑制新陈代谢的募集。自身反应性淋巴细胞进入中枢神经系统（CNS）。这些方法可以有效治疗自身免疫性脑脊髓炎（EAE），这是研究动物MS的基本系统，但它们只能部分抑制人类疾病的进展。尽管如此，现代免疫治疗技术仍然是开发安全MS治疗的最有前途的工具，特别是针对触发疾病发作的细胞因子。